Amgen Presents Denosumab And Sclerostin Antibody Data At American Society For Bone And Mineral Research Annual Meeting; Data Suggest The Potential For Targeting The Key Proteins, RANK Ligand And Sclerostin, For Bone Loss Conditions

PHILADELPHIA--(BUSINESS WIRE)--Sept. 19, 2006--Amgen (NASDAQ:AMGN), the world’s largest biotechnology company, announced today the presentation of data at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting highlighting its expertise in bone biology research and commitment to developing therapies that address the burden of bone disease. The studies evaluated denosumab and a sclerostin antibody, two of the company’s investigational therapies. These antibodies target key proteins responsible for the regulation of bone destruction and formation.